- Home
- VSTD vs ALLR Comparison
VSTD vs ALLR Comparison
Compare VSTD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTD
- ALLR
- Stock Information
- Founded
- VSTD 2016
- ALLR 2004
- Country
- VSTD United States
- ALLR United States
- Employees
- VSTD N/A
- ALLR N/A
- Industry
- VSTD Restaurants
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- VSTD Consumer Discretionary
- ALLR Health Care
- Exchange
- VSTD Nasdaq
- ALLR Nasdaq
- Market Cap
- VSTD 17.9M
- ALLR 20.2M
- IPO Year
- VSTD 2022
- ALLR N/A
- Fundamental
- Price
- VSTD $1.19
- ALLR $1.40
- Analyst Decision
- VSTD
- ALLR Strong Buy
- Analyst Count
- VSTD 0
- ALLR 1
- Target Price
- VSTD N/A
- ALLR $9.25
- AVG Volume (30 Days)
- VSTD 152.5K
- ALLR 337.6K
- Earning Date
- VSTD 11-18-2025
- ALLR 11-13-2025
- Dividend Yield
- VSTD N/A
- ALLR N/A
- EPS Growth
- VSTD N/A
- ALLR N/A
- EPS
- VSTD N/A
- ALLR N/A
- Revenue
- VSTD $13,902,861.00
- ALLR N/A
- Revenue This Year
- VSTD N/A
- ALLR N/A
- Revenue Next Year
- VSTD N/A
- ALLR N/A
- P/E Ratio
- VSTD N/A
- ALLR N/A
- Revenue Growth
- VSTD 30.39
- ALLR N/A
- 52 Week Low
- VSTD $0.68
- ALLR $0.61
- 52 Week High
- VSTD $5.63
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- VSTD N/A
- ALLR 41.82
- Support Level
- VSTD N/A
- ALLR $1.40
- Resistance Level
- VSTD N/A
- ALLR $1.53
- Average True Range (ATR)
- VSTD 0.00
- ALLR 0.11
- MACD
- VSTD 0.00
- ALLR -0.03
- Stochastic Oscillator
- VSTD 0.00
- ALLR 13.05
About VSTD Vestand Inc. Class A Common Stock
Vestand Inc is a California-based Vestand is a fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.